Table 1.
Clinical characteristics and laboratory findings between ILD and non‐ILD groups in patients with anti‐synthetase syndrome (ASS).
| Variables | ASS (n = 119) | ILD (n = 111) | Non‐ILD (n = 8) | p valuea |
|---|---|---|---|---|
| Female, n (%) | 88 (73.9) | 81 (73) | 7 (87.5) | 0.679 |
| Age of onset, median (IQR), years | 54.0 (50.0, 60.0) | 54.0 (50.0, 60.0) | 46.5 (35.5, 52.5) | 0.034 |
| Duration, median (IQR), months | 24.0 (6.0, 48.0) | 24.0 (6.0, 48.0) | 6.0 (2.5, 24.0) | 0.146 |
| Smoking history, n (%) | 12 (10.1) | 12 (10.8) | 0 (0) | 1.000 |
| Alcohol history, n (%) | 5 (4.2) | 5 (4.5) | 0 (0) | 1.000 |
| Contact history, n (%) | 6 (5) | 6 (5.4) | 0 (0) | 1.000 |
| ILD, n (%) | 111 (93.3) | |||
| RP‐ILD, n (%) | 28 (23.5) | 25 (22.5) | 0 (0) | 0.201 |
| Pulmonary symptoms (cough/sputum/dyspnea), n (%) | 111 (93.3) | 107 (96.4) | 4 (50.0) | <0.001 |
| Arthritis, n (%) | 59 (49.6) | 53 (47.7) | 6 (75.0) | 0.163 |
| Myositis, n (%) | 53 (44.5) | 51 (45.9) | 2 (25.0) | 0.296 |
| Fever, n (%) | 13 (10.9) | 12 (10.8) | 1 (12.5) | 1.000 |
| Triad, n (%) | 35 (29.4) | 35 (31.5) | 0 (0) | 0.103 |
| Mechanic's hands, n (%) | 67 (56.3) | 63 (56.8) | 4 (50.0) | 0.728 |
| Shawl sign, n (%) | 7 (5.9) | 7 (6.3) | 0 (0) | 1.000 |
| V sign, n (%) | 10 (8.4) | 7 (6.3) | 3 (37.5) | 0.019 |
| Gottron's papule, n (%) | 20 (16.8) | 19 (17.1) | 1 (12.5) | 1.000 |
| Heliotrope rash, n (%) | 17 (14.3) | 14 (12.6) | 3 (37.5) | 0.087 |
| Raynaud's phenomenon, n (%) | 18 (15.1) | 15 (13.5) | 3 (37.5) | 0.100 |
| RF, median (IQR), IU/mL | 10.1 (10.1, 11.2) | 10.1 (10.1, 11.2) | 10.1 (9.0, 14.3) | 0.513 |
| ACPA, median (IQR), RU/mL | 25.0 (25.0, 25.0) | 25.0 (25.0, 25.0) | 25.0 (25.0, 25.0) | 0.960 |
| ESR, median (IQR), mm/h | 27.0 (15.5, 48.5) | 26.0 (15.0,48.5) | 35.5 (21.0, 62.0) | 0.474 |
| CRP, median (IQR), mg/L | 7.7 (3.3, 33.8) | 6.8 (3.3, 32.5) | 11.0 (5.6, 66.4) | 0.265 |
| ALT, median (IQR), units/L | 24.0 (17.0, 41.0) | 24.0 (17.0, 41.0) | 25.5 (20.5, 35.0) | 0.915 |
| AST, median (IQR), units/L | 24.0 (19.0, 38.0) | 24.0 (19.0,37.0) | 27.5 (17.5, 52.5) | 0.937 |
| CK, median (IQR), units/L | 141.0 (42.0, 454.5) | 143.0 (42.0, 452.0) | 67.5 (36.0, 590.0) | 0.656 |
| CK‐MB, median (IQR), ng/mL | 12.8 (7.5, 23.8) | 13.0 (8.5, 24.0) | 8.0 (4.9, 13.6) | 0.208 |
| LDH, median (IQR), units/L | 257.0 (193.0, 321.5) | 257.0 (194.5, 321.5) | 226.0 (148.5, 337.0) | 0.402 |
| αHBDH, median (IQR), units/L | 174.0 (132.5, 235.5) | 174.0 (134.0, 235.5) | 142.0 (101.5, 230.5) | 0.301 |
| FER, median (IQR), ng/mL | 181.4 (112.5, 364.1) | 181.4 (107, 1364.1) | 209.8 (127.7, 336.4) | 0.629 |
| ANA, n (%) | 94 (79) | 88 (79.3) | 6 (75.0) | 0.674 |
| Anti‐Ro52 antibody, n (%) | 76 (63.9) | 72 (64.9) | 4 (50.0) | 0.458 |
Abbreviations: ACPA, anti‐citrullinated protein autoantibodies; ALT, alanine aminotransferase; ANA, anti‐nuclear antibodies; ASS, anti‐synthetase syndrome; AST, aspartate aminotransferase; CK, creatine kinase; CK‐MB, creatine kinase‐myocardial band; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; FER, ferroprotein; αHBDH, α‐hydroxybutyrate dehydrogenase; ILD, interstitial lung disease; IQR, interquartile range; LDH, lactic dehydrogenase; RF, rheumatoid factor; RP‐ILD, rapidly progressive interstitial lung disease.
a
p between ILD and non‐ILD groups.